Monteverde & Associates Investigates RAPT Sale to GSK, Shareholders to Receive $58 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Shareholder Recovery: Monteverde & Associates has recovered millions for shareholders, showcasing its success in the securities class action field, which has elevated its ranking to a Top 50 firm in the 2024 ISS Securities Class Action Services Report.
- Transaction Investigation: The firm is investigating the sale of RAPT Therapeutics, Inc. to GSK plc, with RAPT shareholders expected to receive $58 in cash per share, aiming to ensure the fairness and legality of the deal.
- Legal Service Transparency: Monteverde emphasizes that its legal services are free and carry no cost or obligation, aiming to attract more shareholders for consultations and potential legal actions.
- Headquarters Advantage: Located in the Empire State Building, the firm leverages its national class action experience and successful litigation record to enhance its influence and trust in the securities law sector.
Analyst Views on RAPT
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 67.78 USD with a low forecast of 56.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.100
Low
56.00
Averages
67.78
High
95.00
Current: 35.100
Low
56.00
Averages
67.78
High
95.00
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
